World journal of urology · 2026
Partial vs. whole-gland salvage hifu after radiotherapy failure: oncological and functional outcomes.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maillard Cyriel, Mebroukine Samy, Haaser Thibaud, Pasticier Gilles, Robert Grégoire, Bladou Franck
Аннотация
PURPOSE: To evaluate the long-term oncological and functional outcomes of whole-gland and partial-gland salvage high-intensity focused ultrasound (S-HIFU) in patients with radiorecurrent prostate cancer, for whom local recurrence after radiotherapy remains a major therapeutic challenge and radical salvage surgery is associated with substantial morbidity.
METHODS: We performed a retrospective single-center study including 138 patients treated with S-HIFU between August 2006 and October 2023 for biopsy-proven local recurrence without metastatic disease. Treatments consisted of whole-gland or partial-gland ablation, including hemi-gland and focal therapy. Oncological outcomes were assessed using Kaplan-Meier analyses and multivariable Cox regression models evaluating progression-free survival (PFS), metastasis-free survival (MFS), and cancer-specific survival (CSS). Postoperative complications were graded according to the Clavien-Dindo classification.
RESULTS: After a median follow-up of over five years, 5-year PFS, MFS, and CSS rates were 43.6%, 85%, and 95%, respectively. Higher pre-HIFU prostate-specific antigen (PSA) levels and ISUP grade ≥ 5 independently predicted disease progression. No significant differences in PFS or MFS were observed between whole-gland and partial-gland treatments. Acute urinary retention occurred in 33% of patients and voiding dysfunction in 39.9%, requiring surgical management in 34.1% of cases. Severe complications were significantly more frequent after whole-gland compared with partial-gland S-HIFU (48.3% vs. 29.8%, p < 0.05).
CONCLUSION: S-HIFU represents a viable salvage option after radiotherapy failure. Our results support that partial-gland S-HIFU significantly reduces severe morbidity while maintaining comparable oncological outcomes compared to whole-gland S-HIFU in appropriately selected patients.
METHODS: We performed a retrospective single-center study including 138 patients treated with S-HIFU between August 2006 and October 2023 for biopsy-proven local recurrence without metastatic disease. Treatments consisted of whole-gland or partial-gland ablation, including hemi-gland and focal therapy. Oncological outcomes were assessed using Kaplan-Meier analyses and multivariable Cox regression models evaluating progression-free survival (PFS), metastasis-free survival (MFS), and cancer-specific survival (CSS). Postoperative complications were graded according to the Clavien-Dindo classification.
RESULTS: After a median follow-up of over five years, 5-year PFS, MFS, and CSS rates were 43.6%, 85%, and 95%, respectively. Higher pre-HIFU prostate-specific antigen (PSA) levels and ISUP grade ≥ 5 independently predicted disease progression. No significant differences in PFS or MFS were observed between whole-gland and partial-gland treatments. Acute urinary retention occurred in 33% of patients and voiding dysfunction in 39.9%, requiring surgical management in 34.1% of cases. Severe complications were significantly more frequent after whole-gland compared with partial-gland S-HIFU (48.3% vs. 29.8%, p < 0.05).
CONCLUSION: S-HIFU represents a viable salvage option after radiotherapy failure. Our results support that partial-gland S-HIFU significantly reduces severe morbidity while maintaining comparable oncological outcomes compared to whole-gland S-HIFU in appropriately selected patients.